Overexpression of the immunosuppressive
cytokine transforming growth factor beta (
TGF-beta) is one strategy that
tumors have developed to evade effective immunesurveillance. Using transplantable models of breast and
colon cancer, we made the unexpected finding that CD8+ cells in
tumor-bearing animals can directly promote
tumorigenesis, by a mechanism that is dependent on
TGF-beta. We showed that CD8+ splenocytes from
tumor-bearing mice expressed elevated
interleukin (IL)-17 when compared with naive mice, and that CD8+ T cells could be induced to make
IL-17 on addition of
TGF-beta and
IL-6 in vitro. Treatment of mice with anti-
TGF-beta antibodies in vivo reduced
IL-17 expression both in the
tumor and the locoregional lymph nodes. Although
IL-17 has not previously been shown to act as a survival factor for epithelial cells, we found that
IL-17 suppressed apoptosis of several tumor cell lines in vitro, suggesting that this altered T-cell polarization has the potential to promote
tumorigenesis directly, rather than indirectly through inflammatory sequelae. Consistent with this hypothesis, knockdown of the
IL-17 receptor in 4T1 mouse
mammary cancer cells enhanced apoptosis and decreased
tumor growth in vivo. Thus, in addition to suppressing immune surveillance,
tumor-induced
TGF-beta may actively subvert the CD8+ arm of the immune system into directly promoting
tumor growth by an IL-17-dependent mechanism.